Neurocrine Biosciences Maps 2026 Execution, “Data-Rich” 2027; Ingrezza Guides $2.7B–$2.8B.
Share this article
Corporate
Score 75
Bullish
Neurocrine Biosciences Maps 2026 Execution, “Data-Rich” 2027; Ingrezza Guides $2.7B–$2.8B
Mar 21, 2026 04:03 UTC
NBR, XLV, IHF, SPY
Medium term
Related Articles
Score 72
Bullish
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
Mar 21, 23:33
Score 25
Bullish
Why Scholastic Stock Climbed This Week
Mar 21, 23:27
Score 65
Bullish
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
Mar 21, 23:15
Score 75
Bullish
Qualcomm Stockholders Back Board, Equity Plan; CEO Amon Highlights AI, Robotics and Data Center Push
Mar 21, 23:03
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.